Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosoppressanti - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - sera immuni u immunoglobulini, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. ara t-taqsimiet 4. 4 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - limfoma, follicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmoloġiċi - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - aġenti antineoplastiċi - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influwenza, bniedem - vaċċini kontra l-influwenza, influwenza, ħaj attenwat - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. l-użu ta 'fluenz tetra għandu jkun ibbażat fuq rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

cangene europe limited - immunoglobulina tal-epatite b umana - immunization, passive; hepatitis b - immunoglobulini speċifiċi - immunoprophylaxis ta 'l-epatite b fil - każ ta' espożizzjoni aċċidentali mhux pazjenti immunizzati (inklużi l-persuni li t-tilqima isincomplete jew status mhux magħruf). - fil-pazjenti fuq emodijalisi, sakemm it-tilqima għandha ssir effettiva. - fil-twelid tal-virus epatite b trasportatur ta'l-omm. - f'pazjenti li ma jurux rispons immuni (l-ebda li jistgħu jitkejlu l-epatite b ' antikorpi) wara t-tilqim u li għalihom kontinwu il-prevenzjoni hija meħtieġa minħabba l-kontinwu riskju li jiġu infettati bl-epatite b. konsiderazzjoni għandha tingħata wkoll għall-oħra, il-gwida uffiċjali fuq l-użu xieraq tal-bniedem ta 'l-epatite b' immunoglobulina għall-użu għal ġol-muskoli.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ucb pharma s.a. - rotigotine - restless legs syndrome; parkinson disease - mediċini kontra l-parkinson - marda ta 'parkinson: neupro huwa indikat għat-trattament tas-sinjali u s-sintomi ta' marda ta 'parkinson idjopatika fi stadju bikri bħala monoterapija (i. mingħajr levodopa) jew flimkien ma 'levodopa, i. matul il-kors tal-marda, permezz li stadji tard meta l-effett ta ' ticlopidine hydrochloride wears off jew issir inkonsistenti u l-oxxillazzjonijiet ta ' l-effett terapewtiku jiġru (tmiem ta ' l-oxxillazzjonijiet doża jew "fuq off"). kwiet-sindrome tas-saqajn: neupro huwa indikat għall-kura sintomatika ta moderata għal severa idjopatika kwiet-sindrome tas-saqajn fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ucb pharma s.a.   - rotigotine - restless legs syndrome; parkinson disease - mediċini kontra l-parkinson - leganto huwa indikat għat-trattament sintomatiku ta 'sindromu idjopatiku moderat għal sever idjopatiku fl-adulti. leganto huwa indikat għat-trattament tas-sinjali u s-sintomi tal-istadju bikri tal-marda idjopatika ta ' parkinson bħala monoterapija (i. mingħajr levodopa) jew flimkien ma 'levodopa, i. matul il-kors tal-marda, permezz ta'l-aħħar stadji meta l-effett ta ' levodopa jonqos ħafna jew isir inkonsistenti u l-varjazzjonijiet tal-effett terapewtiku jseħħu (fl-aħħar tad-doża jew 'on-off' varjazzjonijiet).